ReviewDigestive diseases and sciences2016
Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities.
Review in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Pooled it
- Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort study.EClinicalMedicine · 2025Article
- Increased colorectal and endometrial cancer rates in a genomically ascertained Lynch syndrome cohort.JNCI cancer spectrum · 2025Article
- "Go ahead and screen" - advice to healthcare systems for routine lynch syndrome screening from interviews with newly diagnosed colorectal cancer patients.Hereditary cancer in clinical practice · 2023Article
- Article
- Article
- Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- When guidelines face reality - Lynch syndrome screening in the setting of public health system in a developing country.Journal of community genetics · 2022Article
- Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas.Journal of clinical pathology · 2021Article
- Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system.Cancer medicine · 2020Article
- Suboptimal Adherence in Clinical Practice to Guidelines Recommendation to Screen for Lynch Syndrome.Digestive diseases and sciences · 2019Article
- Cancer communication research in the era of genomics and precision medicine: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Article
- Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.Familial cancer · 2017Article
- Recent advances in understanding Lynch syndrome.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lynch syndrome (LS) is the most common heritable colorectal cancer (CRC) syndrome, accounting for approximately 3 % of CRC cases in the USA each year. LS results from a genetic mutation in one of the four mismatch repair genes, and clinically LS is associated with CRC and other gastrointestinal and extra-gastrointestinal malignancies. In this review, we describe the various clinical criteria utilized for the identification of LS patients and the inherent flaws with these criteria. We discuss the concept of universal testing for LS in all cases of newly diagnosed CRC, along with the potential benefits and challenges of universal testing. Several studies have shown that universal tumor testing is cost-effective and identifies cases of LS that are missed using traditional clinical criteria, which may result in reduced cancer mortality for probands and their families. Yet the full benefits of universal tumor testing may be limited by the availability and patient acceptance of genetic testing, and by logistical obstacles affecting the implementation of universal testing programs. Lastly, we comment on developing technologies such as massively parallel next-generation sequencing, which permits simultaneous sequencing of multiple genes involved in LS and other inherited colon cancer syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.